Immunohistochemical indicators of breast cancer include estrogen receptor ER, progesterone receptor PR, human epidermal growth factor receptor 2HER2 and several other indicators.
Immunohistochemistry is known as immunohistochemistry, and its detection indexes are more diverse, including estrogen receptor ER, progesterone receptor PR, human epidermal growth factor receptor 2HER2, E-calmodulin, P120 protein, and other kinds of indexes.
Breast cancer immunohistochemistry can accurately differentiate some breast cancer histologic types. For example, typical lobular carcinoma in situ is very similar to low-grade intraductal carcinoma in situ of the breast, which can be distinguished by immunohistochemical staining for E-calmodulin and P120.
In addition, immunohistochemistry can be used to identify the patient population that will benefit from therapeutic measures such as endocrine therapy and targeted therapy as well as to predict prognosis. Positively stained tumor cells with hormone receptor ER or PR ≥1% suggests a positive receptor test and should receive postoperative adjuvant endocrine therapy.
Immunohistochemistry test results need to be determined by a medical professional; timely hospitalization is recommended for suspected breast cancer.